NRG
EDIT icon

Nemes Rush Group’s Editas Medicine EDIT Stock Holding History

Nemes Rush Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124 Hold
50
– – ﹤0.01% 927
2025
Q4 		$103 Hold
50
– – ﹤0.01% 970
2025
Q3 		$174 Hold
50
– – ﹤0.01% 670
2025
Q2 		$110 Hold
50
– – ﹤0.01% 709
2025
Q1 		$58 Hold
50
– – ﹤0.01% 699
2024
Q4 		$64 Hold
50
– – ﹤0.01% 718
2024
Q3 		$371 Hold
50
– – ﹤0.01% 577
2024
Q2 		$234 Hold
50
– – ﹤0.01% 589
2024
Q1 		$371 Hold
50
– – ﹤0.01% 637
2023
Q4 		$507 Hold
50
– – ﹤0.01% 624
2023
Q3 		$390 Hold
50
– – ﹤0.01% 619
2023
Q2 		$412 Buy
+50
New +$436 ﹤0.01% 645

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nemes Rush Group's EDIT Position: Q1 2026 in Review

Nemes Rush Group held its Editas Medicine (EDIT) position steady in Q1 2026 at 50 shares worth $124. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Nemes Rush Group first reported a position in EDIT in Q2 2023 and has held it in 12 quarters since. The position peaked at $507 in Q4 2023. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Nemes Rush Group held 50 shares of Editas Medicine worth $124 as of Q1 2026.
  • Nemes Rush Group left its Editas Medicine share count unchanged in Q1 2026.
  • Editas Medicine made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #927 holding.
  • Nemes Rush Group first reported a position in Editas Medicine in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Editas Medicine position peaked at $507 in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.